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Abstract
Background: Surveys of doctors suggest that they use placebos and placebo effects clinically to help patients. However,
patients’ views are not well-understood. We aimed to identify when and why placebo-prescribing in primary care might be
acceptable and unacceptable to patients.
Methods: A purposive diverse sample of 58 English-speaking adults (18 men; aged 19–80 years) participated in 11 focus
groups. Vignettes describing doctors prescribing placebos in primary care were used to initiate discussions. Data were
analyzed inductively.
Results: Participants discussed diverse harms and benefits of placebo-prescribing for individual patients, carers, healthcare
providers, and society. Two perspectives on placebo-prescribing were identified. First, the ‘‘consequentialist’’ perspective
focused on the potential for beneficial outcomes of placebo-prescribing. Here, some participants thought placebos are
beneficial and should be used clinically; they often invoked the power of the mind or mind-body interactions. Others saw
placebos as ineffective and therefore a waste of time and money. Second, the ‘‘respecting autonomy’’ perspective
emphasized the harms caused by the deceptive processes thought necessary for placebo-prescribing. Here, participants
judged placebo-prescribing unacceptable because placebo-prescribers deceive patients, thus a doctor who prescribes
placebos cannot be trusted and patients’ autonomy is compromised. They also saw placebo-responders as gullible, which
deterred them from trying placebos themselves. Overall, the word ‘‘placebo’’ was often thought to imply ‘‘ineffective’’; some
participants suggested alternative carefully chosen language that could enable doctors to prescribe placebos without
directly lying to patients.
Conclusions: Negative views of placebos derive from beliefs that placebos do not work and/or that they require deception
by the doctor. Positive views are pragmatic in that if placebos work then any associated processes (e.g. mechanisms,
deception) are deemed unimportant. Public education about placebos and their effects is warranted and research to
identify optimal ways of harnessing placebo effects in clinical practice is needed.
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Introduction
Placebo effects can be broadly defined as changes in a person’s
health status that result from the meaning and hope the person
attributes to a procedure or event in a health care setting.[1,2]
These effects can be substantial[3–6] and are mediated by and
involve measurable changes in neurological, immune, and
endocrine systems.[7,8] In clinical research, placebo effects must
be controlled for (using, for example, placebo pills or sham
surgery) but are typically not thought inherently interesting.[9] In
clinical practice, placebo effects may have great relevance and
potential to be harnessed for patient benefit[10,11] and there are
many ways doctors might attempt to do this. One approach is to
enhance patients’ expectations and communicate empathically, for
example when managing pain in primary care[12,13] or when
delivering acupuncture.[14] This paper focuses on another, more
controversial, approach to eliciting placebo effects: prescribing
placebo-like substances such as sugar pills, ‘‘tonics’’ or low dose
vitamins in primary care.
The actual contents of placebos are rarely reported even in
clinical trials.[15] Recent surveys of clinical practice have
distinguished between pure or inactive placebos (e.g. saline
injections, sugar pills) and impure or active placebos (e.g.
nutritional supplements in the absence of established deficiency,
antibiotics for a viral infection).[16–18] The concept of impure
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placebos is however difficult to apply in practice as, for example, it
is not always certain when prescribing antibiotics whether the
patient has a bacterial or viral infection. Furthermore, doctors,
patients, and researchers probably hold different definitions of
placebos and may differ in whether they characterize particular
interventions as being ‘‘real’’ treatments or placebos. [19] Overall,
there remains little consensus regarding the definition of placebos
and this probably contributes to wildly different estimates of the
prevalence of placebo-prescribing in clinical practice. A recent
systematic review found that estimates of the lifetime prevalence of
prescribing pure placebos among doctors ranged from 17% to
80%[20] and it seems that doctors prescribe impure placebos
more frequently than pure placebos.[20,21]
For this study, we focused on scenarios which we believed most
doctors and researchers would agree involve prescribing placebos
in an attempt to elicit a beneficial placebo effect in patients. In
such scenarios ethical issues abound, in particular the dilemma
between principles of beneficence (prescribing placebos could
benefit patients…) and respect for persons (…but prescribing pure
placebos would require deceiving patients).[22–25] However,
recent research confirms earlier suggestions that this dilemma
might have shaky foundations: it might be possible to elicit
clinically meaningful placebo effects in depression and irritable
bowel syndrome by prescribing pure placebos openly without
deceiving patients.[26,27] If these initial findings are substantiated
then this could encourage increased deliberate use of placebos in
clinical practice to elicit placebo effects. What might patients make
of this?
Very little is known about patients’ views on placebos. Most
studies have used quantitative methods[28–34] which cannot offer
an in-depth understanding of patients’ perspectives; qualitative
studies have interviewed participants in clinical trials or experi-
ments[35–38] but these settings are very different from clinical
practice. We therefore conducted a focus group study to explore
how members of the general public discuss placebo-prescribing in
UK clinical practice. We used qualitative methods to discover
inductively the issues that members of the public consider
important. Our results identify when and most importantly why
placebo-prescribing might be acceptable and unacceptable to
patients in UK primary care.
Methods
Design
We chose to use focus groups to elicit lay people’s views on
placebo-prescribing in clinical practice because it is a potentially
contentious topic and we know little about the issues that lay
people deem relevant. Group settings encourage participants to
both present and react to diverse opinions, which can help them to
articulate and justify their own views. Unlike one-to-one
interviews, focus groups thus allow researchers to observe the
negotiation and formation of attitudes and norms within a group
setting and to gain insight into the socially- and culturally-
embedded reasoning processes that contribute to participants’
judgments.[39,40] To facilitate discussion of what could be quite
an abstract and unfamiliar topic, we used short vignettes
describing concrete examples of different ways in which doctors
might prescribe placebos. Given that debates in this area have
focused on the ethics of deception, we devised one vignette
describing deceptive placebo-prescribing and one describing open-
label placebo-prescribing. We also included vignettes about two
contrasting illnesses (common cold and cancer), as we wanted to
encourage participants to think broadly about different situations
in which placebos might be used. Furthermore, as placebos are
typically associated with clinical trials, we also included one
scenario that described the use of placebos in a clinical trial. All of
the vignettes described a doctor prescribing a placebo (rather than,
for example, eliciting placebo responses by communicating
empathically when prescribing an evidence-based condition-
specific treatment). Together these vignettes provided the neces-
sary basis for discussion but did not constrain the groups:
participants were encouraged to introduce additional scenarios
themselves and to adapt the vignettes in order to explore placebo-
prescribing more fully.
Vignette 1: Clinical Practice with Deception. James is a
healthy young man who goes to see Doctor Smith because he has a
headache, a sore throat, and a runny nose. He feels pretty rotten.
Doctor Smith examines him, and decides that James has a cold.
Doctor Smith knows there is nothing seriously wrong with James,
and knows that there is no medicine that will cure his cold. James
will get better in his own time, as his body fights the cold virus.
Doctor Smith gives James a prescription for a tonic anyway, and
tells James that the tonic will help. James takes the tonic and feels
better.
Vignette 2: Clinical Practice without Deception. Jake is
another healthy young man who goes to see his doctor, Doctor
Brown, because he has a headache, a sore throat, and a runny
nose. He feels pretty rotten too. Doctor Brown examines him, and
decides that Jake has a cold. Doctor Brown knows there is nothing
seriously wrong with Jake, and knows that there is no medicine
that will cure his cold. Jake will get better in his own time, as his
body fights the cold virus. Doctor Brown explains all this to Jake.
He then offers to give him a prescription for a tonic, saying that
the tonic has no active medicine in it but might help to make him
feel better anyway. Doctor Brown says that the tonic can be
effective even without any active medicine, just because Jake wants
it to work. Jake takes the tonic and feels better.
Vignette 3: Clinical Practice for Terminal Illness. Annie
has advanced cancer. She has already had surgery, radiation
treatment and chemotherapy. These treatments have given her a
bit more time with her family. Sadly though, there is no cure for
the particular type of cancer that Annie has. Dr Jones is Annie’s
doctor. Dr Jones wants to make sure that Annie is as comfortable
as possible. Annie is still feeling hopeful, and Dr Jones does not
want to dash her hopes. So, Dr Jones gives Annie some vitamin
pills. The pills will not cure Annie’s cancer. Dr Jones tells Annie
that the pills are a type of treatment for people who have cancer.
Vignette 4: Clinical Trials. Medical researchers think that
they might have come up with a new medicine for the common
cold. They don’t know if the new medicine will work or not, so to
do a proper scientific test they have to compare their new
medicine to a placebo medicine. People who have a cold agree to
be in the clinical trial. They are randomly assigned (based on a
coin toss) to get either the new medicine or the placebo medicine.
The new medicine contains drugs that might help cold symptoms
get better. The placebo medicine looks exactly like the new
medicine but it is completely inert. It does not contain any active
drugs. No-one knows which medicine each patient has had until
the end of the trial. John agrees to take part in the trial, and his
cold symptoms do get better. At the end of the trial, it turns out
that he had the placebo medicine.
Ethics Approval
Ethical approval was granted by the host institutions (University
of Southampton and Totton College; ERGO ID584). Written
informed consent was obtained using procedures approved by the
ethics committee. To protect participants’ anonymity, audio-
recordings were destroyed following verification of the transcripts
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and completion of the data analysis. Transcripts were anonymised
immediately (removing participants’ names and other recognizable
details e.g. towns, family members, clubs).
Participants and Procedure
To capture the range of views held by members of the public we
were guided by the concept of maximum variation sampling, an
accepted approach to sampling in qualitative research. This
approach is particularly appropriate when (as was true for the
present study) there is little evidence to suggest in advance which
contextual factors will shape the phenomenon of interest.[41]
Therefore, we attempted to recruit a diverse sample of English-
speaking adults including people who might reasonably be
expected to hold different views on placebos. We aimed to include
people with and without a scientific background; young, middle-
aged and older adults; people from different socio-economic
backgrounds; people with and without chronic illness; and people
living in different regions of England (South, Midlands, South-
West) and in urban (inner city, market town, suburban) and rural
locations. Existing contacts in the community were used to invite
pre-existing groups of people (helping to facilitate comfortable
group discussions). Potential participants were informed of the
study in writing and invited to take part; focus groups were
organized in consultation with the volunteers at convenient
community locations (e.g. a tea-room, village hall). 58 participants
(18 men, 40 women aged 19–80 years) took part in 11 focus groups
that successfully reflected the intended range of characteristics (see
Table 1).
Each focus group was audio-recorded and moderated (i.e.,
facilitated) by AA or LA, alone or with FB. AA and LA received
training in qualitative research and were supervised by FB, who is
an experienced qualitative researcher. The focus group moderator
began by introducing herself (as a researcher interested in public
views on placebos) before providing an overview of ethical issues
(e.g. confidentiality among participants) and obtaining written
informed consent. The moderator then initiated discussion among
the participants by reading aloud one vignette and inviting
comments. The moderator observed as the groups discussed their
views, and put follow-up questions to the groups if necessary in
order to ensure a full discussion and to encourage participants to
explain their thinking in a non-judgmental manner. Broad and
open questions were used for this purpose, for example: ‘How
would you feel if the person had a more serious illness?’ ‘How do
you think the placebo effect works?’ The moderator encouraged
individual participants to speak if necessary to elicit full and
detailed contributions and ensure that all participants had the
opportunity to speak. Groups were brought to a close when all
vignettes had been considered, views had been explored in depth
and participants were satisfied that the important issues had been
discussed.
Data Analysis
Audio recordings were transcribed verbatim and analyzed
inductively for themes.[42] This means that we did not use an a
priori framework to code our data nor did we anticipate in
advance specific themes or categories of talk. Instead, we analysed
the data carefully and with open-minds in order to identify the
issues and arguments that our participants themselves raised. The
analytic process was iterative (i.e., moved forwards and backwards
between different activities) and the six phases outlined by Braun
and Clarke[42] were used to help develop themes that captured
important patterns in the data in relation to participants’ views on
placebo-prescribing in primary care. First, recordings were
listened to and transcripts were read repeatedly and slowly,
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meaning unit by meaning unit[43] and annotated with comments.
A meaning unit is the smallest unit of speech that expresses a single
meaning; often this corresponds with a phrase or a sentence.
Second, inductive (data-driven) initial codes were developed and
applied to all transcripts,[44] and collated in the form of a coding
manual. An example of an inductive code is ‘‘doesn’t matter how
placebo works’’, which was applied to excerpts such as ‘‘I wouldn’t
care whether the placebo worked, it doesn’t matter particularly, as
long as the medicine was a safe medicine. The point is do I get
better? I don’t really care how it happens, to be honest.’’ A coding
manual lists all of the codes, defines each of them and provides an
illustrative excerpt from the raw data. As such, it provides a
transparent record of when each code should be used that forces
researchers to be rigorous and specific in their coding, forms an
important part of the ‘audit trail’ that documents the process of
qualitative analysis and allows for the possibility of replication,[45]
and can facilitate team-working during qualitative analysis. Third,
higher level, more abstract potential themes were developed by
merging and splicing the initial codes. This involved merging
together two or more codes that stood for similar ideas or splicing
them together to form a new potential theme that cut across the
original codes. For example, a new, overarching, potential theme
that was labeled ‘‘Placebos work by psychological mechanisms’’
was created by splicing together a number of codes that described
different psychological mechanisms that participants thought
might contribute to placebo effects, including: ‘‘feel better in your
head’’, ‘‘helps psychologically’’, ‘‘mind over matter’’ and ‘‘positive
thinking’’. At this stage, themes were discussed by at least two
researchers, to ensure that the analysis was not idiosyncratic,
overly narrow, or excessively broad. Fourth, preliminary themes
were reviewed for fit with the coded extracts, each transcript as a
whole, and the entire data corpus. In other words, we checked that
each preliminary theme summarized the ideas expressed in the
excerpts coded under it; we also checked that when taken together
the preliminary themes captured the ideas expressed in each
transcript and across the entire set of transcripts. This ensured our
themes captured the variation in our data, did not overlook any
important issues or perspectives, and were an accurate interpre-
tation of the data. We also reviewed how the preliminary themes
related to each other. At this stage, some preliminary themes were
re-conceptualized as subthemes of larger themes that encompassed
related ideas; for example ‘‘placebos work by psychological
mechanisms’’ and ‘‘role of personal interactions in placebo effects’’
were both conceptualized as subthemes of the theme ‘‘(How) do
placebos work?’’ Fifth, the contents and name of each theme was
finalized. Sixth, the analysis was written up and vivid and typical
illustrative quotes were selected for inclusion in this report.
Procedures used to enhance the rigor of this qualitative analysis
include: maintaining an audit trail (coding was documented in
Atlas.ti which is a software designed to support qualitative analysis;
a coding manual was produced; analytic memos and diagrams
were used to record analytic ideas and decisions); deliberately
searching for exceptions and contradictions to apparent patterns;
having three researchers heavily involved in the analysis; sustained
engagement with the data over time; presenting verbatim quotes
and excerpts to illustrate themes and provide evidence grounding
our interpretation in the data.[46]
Results
In considering whether doctors might legitimately prescribe
placebos in clinical practice, the focus groups discussed both the
process and the likely outcomes of placebo-prescribing. When
either the process or the outcomes were prioritized, clear
judgments were made as to whether doctors should prescribe
placebos. When attempts were made to balance concerns about
both the process and the outcomes, talk about placebo-prescribing
enacted a familiar ethical tension: should doctors tell the whole
truth or should they lie to benefit their patients? More
fundamentally, the notion that placebos can benefit patients was
scrutinized by the groups.
(How) Do Placebos Work?
Participants were unwilling to accept at face value the
statements in our scenarios that implied placebos can benefit
patients, and instead discussed this proposition (and possible
explanations for it) in some detail. In doing so, participants drew
on experiential knowledge gleaned from personal experiences of
taking placebos, responding psychologically to conventional
medicines, and using complementary and alternative medicines,
particularly homeopathy. Participants also discussed more abstract
‘‘facts’’ about placebo effects, which were attributed to academic
studies, radio and television programs; they discussed the role in
illness and healing in general of psychological factors such as stress
and thinking positively; and in some cases they turned to the focus
group moderator to seek a more expert opinion on the veracity of
placebo effects. Those who ultimately agreed that placebos could
benefit patients expressed various models of how such effects might
be achieved. Some models were no more than broad general
notions that reverentially invoked the mysterious powers of the
non-corporeal mind to influence the body, suggesting a degree of
Cartesian duality, which led participants to struggle to compre-
hend how a psychological input could have a physiological effect.
Other models focused on the brain, which seemed to allow a
slightly clearer idea of how physiological effects could be produced
by placebos containing ‘‘inactive’’ ingredients.
‘‘I think these placebos are amazing to be honest these
things because to be honest you know, people get better
without ever having to take medicine just basically by the
powers of their own mind.’’ (FG1)
‘‘I’ve heard a lot about dopamine and taking placebos
causing that to be released and I don’t know what effect
dopamine might have but there might be a mechanism
where, by which (P: Makes you feel better) by which it
actually has a physical effect. I suppose also there’s like
people don’t completely understand the human body so
there might be mechanisms that we don’t even know about
yet which cause people’s mentality to change their physical
condition.’’ (FG8)
Patients’ individual characteristics were discussed as potentially
influencing the effectiveness of placebos, with certain patients
deemed more likely to respond well to a placebo than others.
Some but not all of these judgments were somewhat derogatory:
for example when talking about a character in the vignettes ‘‘I
don’t think he is very bright’’ (FG4) and ‘‘some patients need that
psychological help’’ (FG6). When individual differences in placebo
response were thought to be predictable, doctors who knew their
patients well were seen as having an important role in ensuring
that placebos are given to people who would benefit from them.
‘‘If he was one of those patients that the doctor knew would
expect something and would get better quicker because he’s
been given something, I don’t see any harm in that.’’ (FG4)
Patients’ Views on the Acceptability of Placebo-Prescribing
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The doctor-patient relationship was also seen as integral to the
placebo effect itself. From this perspective, placebo effects were
attributed to the doctor as a trusted authority figure providing
reassurance and a positive message about recovery. This seemed
to be a particularly accessible model of placebo effects, which
participants could relate to. Indeed, some recounted their own
experiences of reassurance from a trusted doctor leading to
immediate improvements in wellbeing and symptoms.
‘‘I don’t know whether it is a placebo effect but sometimes
you can go to the doctor feeling dreadful you know and you
think oh there must be something seriously wrong, all these
headaches, this pain and that pain and the other and you get
there and you start to explain it and suddenly he sort of he’ll
go ‘‘oh, well that’s because it’s just your circulation which is
a problem when you get older and that’s this, is that’’ and by
the end after 5 minutes you come out thinking I don’t know
why I ever went, I feel better already, really there’s nothing
wrong with me much.’’ (FG8)
Consequentialist Perspectives: Effective Placebos are
Acceptable in Clinical Practice
Placebos were only judged acceptable in clinical practice in
certain circumstances, essential among which was the perception
that placebos can benefit the patient. Some participants demon-
strated a particularly strong consequentialist perspective, arguing
that as long as placebos benefit the patient then they should be
used in clinical practice. They prioritized potential benefits over
other issues, including mechanisms of action and (dis)honesty.
‘‘I don’t think it matters as long as it works.’’ (FG1)
‘‘The point is do I get better? I don’t really care how it
happens, to be honest.’’ (FG8)
In the context of serious illness, some participants also drew on a
discourse of desperation to justify placebo-prescribing: provided
the patient might benefit and certain other conditions were
satisfied, they considered it would be ‘‘worth trying’’ placebos as a
last resort. The necessary additional conditions for placebos to be
acceptable here included the lack of any proven effective
treatment, the placebo not causing harm, and the person being
in pain or otherwise suffering.
‘‘It depends how bad you’re feeling – if you’re feeling really
bad, you might be at the point where it’s just like I’ll try
anything. I just want to get better.’’ (FG1)
‘‘If it’ll help, it’ll help and if there’s no active medication that
works, as long as it’s not harmful it can only be helpful.’’
(FG6)
While effective placebos were acceptable to those taking a
consequentialist perspective, the converse was also true: not
surprisingly, when placebos were perceived as powerless or
unnecessary, their use was deemed unacceptable. Some partici-
pants argued that because placebos lack active ingredients, they
cannot ‘‘work’’ or have any effect on patients’ health, which again
was reminiscent of a Cartesian model in which a physical agent of
change must be introduced to have a meaningful effect on
symptoms. When placebos were deemed powerless, their use was
seen as a waste of time and money that would be better spent on
‘‘real’’ treatment.
‘‘I wouldn’t - personally I wouldn’t take it - because what is
the point? It’s a waste of money and a waste of resources. So
no, I wouldn’t do it.’’ (FG9)
‘‘If the tonic hasn’t really got any active ingredient, then it’s
not actually honest and I wouldn’t want someone giving me
something, you know, say it’s going to make me better when
actually it’s of no use at all.’’ (FG5)
Respecting Patients’ Autonomy: Deceptive Placebo-
Prescribing is Unacceptable in Clinical Practice
Almost all participants suggested that placebo-prescribing must
be deceptive in order to be effective. When participants prioritized
the deceptive nature of the prescribing process over other issues
they judged placebo-prescribing unacceptable. Deceptive pre-
scribing was seen as threatening a patient’s right to self-
determination and autonomy; doctors who prescribed placebos
deceptively were seen as acting in an overly paternalistic
patronizing way, making decisions for (instead of with) patients,
not allowing patients the opportunity to fully comprehend their
situation, and taking away patients’ right to choose their own
health care. Deceptive placebo-prescribing was condemned on
these grounds across diverse scenarios by participants in all focus
groups.
‘‘the doctor must explain it and it would be very wrong to
give somebody treatment that was inappropriate, very
wrong. It’s dishonest and it ruins the relationship between
doctor and patient. It’s much better to be honest about it.’’
(FG10)
‘‘I would be furious, I have to say, if I did go to the GP and
wanted – needed medication and I don’t take medication at
all unless I absolutely have to; if I do go and then find
afterwards that it had been a placebo, without my
permission, I would want to sue, I would be so angry.’’ (FG2)
Interestingly, there was one clear exemption from the require-
ment to respect a patient’s autonomy and therefore not to
prescribe placebos deceptively: when the recipient is a child. This
is consistent with children’s legal status in medical situations in
which parental informed consent is necessary and child assent is
desirable. Participants generally recognized that placebos are
frequently given to children by their carers, citing examples of
‘magic plasters’ and ‘magic kisses’, and held the view that children
are also more likely than adults to believe a placebo will make
them feel better.
‘‘Loads of times - like, especially when you’re a kid, things
like the magic kiss, where you have a fall or there is Calpol
which is sugar, or there is like a certain like, my mother had
us convinced that jelly tots were like going to make us better
- regardless of the illness.’’ (FG6)
The only situation in which placebos were universally accepted
was clinical trials. Although not the focus of this paper, it is
relevant to note here that all of the focus groups were generally
accepting of placebos in clinical trials, based on the assumption
that patients would be fully informed and give consent.
Patients’ Views on the Acceptability of Placebo-Prescribing
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‘‘It’s a trial which I think it’s fine, I’ve got no objection about
it being given in a trial at all because you know what you’re
signing up for.’’ (FG4)
Fine Lines and Tightropes: Weighing Benefits and Harms
When participants considered both the process and outcomes of
placebo-prescribing they attempted to weigh benefits and harms,
which were broadly construed in relation to the individual patient,
their family, the patient-doctor relationship, and society at large.
In weighing benefits and harms some groups and individual
participants oriented to a tension between (a) wanting doctors to
be honest (to respect patients’ autonomy) and (b) wanting doctors
to do everything possible to help their patients. Participants
recognized the potential for beneficial health outcomes from
taking placebos and for harm from the deceptive prescribing
process. Table 2 summarizes the diverse benefits and harms of
placebo-prescribing that were discussed in the focus groups. The
following excerpt from focus group 5 illustrates how these benefits
and harms were debated in interaction.
P1: But placebos will only work if the doctor is dishonest.
The question is - that if the, if it was just a common cold it
will be cured in time, the body will cure itself; in that case
dishonesty’s justified I think, give out placebo, by all means
and then, then make them believe it. I mean you certainly
don’t say that it doesn’t contain any active ingredients. You
don’t tell them that.
P2: Well actually the doctor is saying that I haven’t got
anything that will cure you, but I do know that if you go
home and have some whiskey and hot water with a bit of
honey in it, it won’t do you any good, but it will make you
feel better.
P1: Yeah, yeah I’m not, not saying that placebos should be
given, but I don’t see any moral, any, any moral
condemnation of placebos. I mean I don’t think it’s immoral
of the doctor to give a placebo if he’s convinced that the
man has got nothing seriously wrong with him, but if he
thinks that the man will be happy, then don’t tell him that
it’s got no active ingredients, say here’s this, try this, you.
The doctor won’t say this will cure you, all a doctor will say
is try this you might get better.
P3: This may make the underlying problem worse cause
then the person then becomes totally dependent on the
doctor giving him something that isn’t actually, is nothing
more than a bit of TLC. (FG5)
In the context of minor illness (a common cold), a more
moralistic discourse appeared in which placebo-prescribing was
seen as harmful in that it wasted resources, represented
unnecessary medicalization of minor illness and encouraged
dependence on doctors. These participants saw the common cold
as a minor self-resolving condition which patients were obliged to
self-manage (e.g. through rest and home remedies) without seeking
professional medical care.
‘‘I don’t think he really should’ve given him anything. He
should tell him that he doesn’t need anything, he’s got a
common cold and it will get better naturally.’’ (FG4)
Discussions of benefits and harms were particularly lively when
participants considered the (deliberately provocative) vignette in
which a patient with terminal cancer was prescribed vitamins as a
placebo after having completed conventional treatment. While all
but one group initially reacted very negatively to this scenario
(suggesting possible consensus against placebo-prescribing in this
situation), as discussions continued more diverse views were
articulated. The language used in these discussions evoked
dilemmas, with participants speaking of ‘‘tightropes’’ and ‘‘fine
lines’’. In terminal illness in particular, the dilemma was between
the doctor being honest (but destroying hope) and providing
benefit (but creating false hope). Uncertainty abounded in these
discussions and consensus around a clear judgment on accept-
ability was rarely achieved, as illustrated by the following excerpt
from focus group 7.
P3: Yeah, I agree with that but it’s also kind of deception as
well and it’s not really fair. But as I said, it’s with the best
intentions. But it is morally weird.
P2: Yeah, I think you’ve said it already but what it comes
down to is the pain on one side and just the truth –
P3: Yeah
P4: But you’re assuming that the placebo’s going to have an
effect on the pain aren’t you? Is a placebo just to do with
pain, or is it more to do with your mood, your positive-ness
and your general wellbeing?
P2: I think that would overcome the pain if she believes in
the placebo, the pain level could be the same but like you
said before with the positive, you know -
P4: How do you know? [interrupting]
P2: Mental attitude. You don’t know, you can’t know. But
I’m sure, you know, they would have one-to-ones with their
patients and if the feedback’s a lot more positive then um I
think I don’t, well I do see a problem, but I see how it
benefits. (FG7)
Some focus groups suggested that careful use of language might
resolve the dilemma: if doctors are vague or tentative in how they
describe placebos then they might be able to use them to elicit
placebo effects without directly lying to patients. In other words,
some participants suggested that careful wording (or ‘‘fudging’’ the
truth) could be a way of avoiding ‘‘blatant’’ lies and thus rendering
placebo-prescribing acceptable. This resolution was not satisfac-
tory for all participants and there was considerable variation in the
interpretation of particular words. For example, some considered
‘‘treatment’’ to imply cure while others considered it to imply
merely that the substance might help the patient in some way.
Other terminology and phrasings were also interpreted in diverse
ways and the very term ‘‘placebo’’ was itself problematic. For
some, ‘‘placebo’’ was to be avoided at all costs; for others, avoiding
the word ‘‘placebo’’ constituted unacceptable deception. Many
participants believed that using the term ‘‘placebo’’ would render
placebos powerless.
‘‘You can tell a person in so many words this is a placebo but
if you don’t say this is a placebo, they still hold on to a
glimmer of hope. But when you say placebo people just stop
believing it’ll work at all, and they’ll almost fight it. They’ll
want it to not work just to prove that they can’t be
influenced by the placebo.’’ (FG6)
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Table 2. Benefits and Harms of Placebo-Prescribing as Discussed in Focus Groups.
Perceived Consequence of
Placebo-Prescribing Illustrative Quotation
Benefits
Financial – for the NHS Can I just go back to what you were saying, that that is an issue isn’t it now, with the cost of the NHS; if a placebo is costing
you a pound to give out and they’re [patients are] paying £7.40, that could bring a lot of revenue for the NHS. (FG2)
Alleviate discomfort ‘‘I’d want them (an elderly person) to feel as comfortable as possible’ FG5
Benefits for carers ‘I have a parent who’s crippled by arthritis and it’s very severe, very nasty now, I think it’s probably past the point of, very
much, of being able to do very much about it; but I feel that by administering a placebo to one parent, the other parent
probably benefits on the care side of things as well’ FG2
Feeling cared for, supported ‘‘Or is the doctor treating the needs of his patients? He knows that some people just say ‘right, I’ll work through a cold’.
whereas that patient needs a bit of caring, that little bit of showing - by giving them the tonic it’s showing caring for his -
and treating it like it is a real illness, so maybe there is an element of benefit in that. You know sometimes people want to be
listened to or felt that someone’s helping them, that could be a consideration, that the tonic, while it’s not medically helping
them, it’s emotionally helping them.’’ (FG2)
General mood I:OK. What effects do you think a placebo can have on people?
MP: Just your general mood, if you believe you’re being treated for something that’s going to lift your spirits a little bit
(FG11)
Symptom improvement But she might believe it and then - be happy. Might relieve her pain when nothing else is available to do that. (FG7)
Avoids risk of addiction associated with
pharmaceuticals
‘if the alternative to a placebo is something strong, like morphine, then I’d rather the placebo first, as morphine is addictive’.
(FG5)
No adverse effects You’ve also got that - the other advantage of - by giving them a pill they think they feel better, they’re also not getting any
of the side-effects. (FG2)
Maintain some hope It’s good to give her a little bit of hope. (FG11)
Reduce need for medicines I just think GPs should never tell you, and just say take this and you’re going to get better by the power of your own mind
then you’ll never have to take medicine again. (FG1)
Harms
Financial – for the patient/NHS MP: It’s disingenuous in today’s context where you’re paying for a prescription and presumably if it’s sugar water it doesn’t
come as expensive as a prescription charge does anyway, so he should tell him to go away and buy a tonic or whatever, you
know, non-prescription drug because with the way that prices and costs of prescriptions are, if the chap finds out that he’s
being given something which is, you know, nothing really, he might be quite cross with the doctor even though he is
feeling better later on. So -
P: I hadn’t thought of prescription charge, because it is a lot.
P: What is a prescription charge?
P: Seven pounds twenty.
Risk of missed/delayed diagnosis ‘‘You’ve hit the nail on the head. It isn’t about like - if it was a cold, it’s a cold, it’s a cold. It’ll be a cold. But if it was like - if it
was that he thought it were a cold and it turns out you had TB, then that’s a completely different situation but as [other
participant] says, that’s where you kind of flit into malpractice.’’ (FG6)
If used as an alternative to proven
treatment
‘‘Well the only negative effect I’d say is when it’s like a critical illness, where a fatality could be a consequence and there is a
medicine that they could take which can battle the cancer and the doctor decides to do a placebo that has no effect.’’ (FG7)
False hope ‘‘If someone’s turned around and given you false hope and said these will help cure your cancer, then it’s a different matter.’’
(FG11)
Patient feels disrespected I would want the truth, I really don’t like being fobbed off as if you’re a nitwit. (FG3)
Threatens trust in doctor if deceit is
discovered
‘I suppose that if he finds that they’re only placebos or sugar pills, then you know, you lose trust in the doctor’. (FG11)
Put off going to doctor in future ‘‘I think there’s a danger though if he’s found out that the doctor tricked him then he might not go to the doctor next time
when it’s something more serious.’’ (FG8)
Encourages over medicalization of minor
illness
‘‘But isn’t it just going to lead to him going to the doctors again because he wants more tonic because he’s got another
cold?’’ (FG7)
Panders to patients’ reliance on doctors ‘Somebody then becomes dependent on them and going to the doctor and getting one of those and that is what I mean
about it being sinister because the whole society’s expecting that something will make them better from whatever they’ve
got all the time’ (FG5)
Unlikely to be effective ‘‘But surely a placebo would only work with a handful of cases.’’ (FG8)
Removes patient choice ‘‘What goes into my body; it’s my body, it’s up to me to decide, it’s up to nobody else at all, you know, they are there to
facilitate my healing, they are not in control of it.’’ (FG2)
doi:10.1371/journal.pone.0101822.t002
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Discussion
Principal Findings
Despite evidence indicating that placebos can be beneficial and
lead to measurable physiological changes, there remains much
professional uncertainty and contradictory views as to whether
they should be used in the clinic. Surveys have also indicated a
range of patient opinions on the acceptability of placebos, but to
date there have been no studies examining the underlying beliefs
that influence either positive or negative views. In this study, we
were interested in determining when and why patients find
placebos acceptable. We showed that uncertainty and contradic-
tory views abound among the community. There was no overall
consensus as to the acceptability of placebo-prescribing, for either
minor self-limiting illness or terminal illness. Participants in our
focus groups espoused two core perspectives. The consequentialist
perspective was pragmatic and focused on the potential outcomes
of placebo-prescribing: if placebos are beneficial, they should be
used in the clinic. Such views were founded on beliefs that
placebo-prescribing can have benefits for patients and ideas about
how placebos might work often invoked the power of the mind or
mind-body interactions. The respecting autonomy perspective em-
phasized the ethical harms caused by the deceptive processes
thought necessary for placebo-prescribing: prescribing placebos in
the clinic is unacceptable because it requires the doctor to deceive
the patient. In their discussions, participants considered many
potential harms and benefits including the implications of placebo-
prescribing for patient and carer wellbeing, NHS and personal
resources, doctor-patient relationships, medicalization of minor
illness, and patient choice and the right to self-determination (for
adults if not children). The word ‘‘placebo’’ was itself problematic
as it was often thought to imply ‘‘ineffective’’; some participants
felt that doctors might be able to use alternative carefully chosen
language to prescribe placebos such that beneficial effects could be
realized without directly lying to patients.
Strengths and Limitations
Using vignettes within focus groups allowed us to introduce a
relatively unfamiliar topic in a way that prompted discussion and
at times lively debate among members of the general public.
Participants expressed and responded to diverse opinions, which
allowed us to observe at first hand the arguments and counter-
arguments that were brought to bear on the controversial topic of
placebo-prescribing. Moreover, unlike surveys, focus groups gave
participants the opportunity to discuss the topic with their peers in
a social setting, to question our assumptions and to raise issues of
importance to them that we – as researchers - might not have
anticipated.
A limitation is that participants were recruited from a small
sample of groups known either directly or indirectly to the
researchers; therefore, the range of opinions expressed in the focus
groups may be limited. The data we obtained, however, did reflect
a wide range of opinions, and participants were recruited from a
variety of ages, educational levels, social groups, and regions of
England. A second limitation is that participants were asked to
discuss hypothetical scenarios (the vignettes). If participants were
offered placebos during a visit to the clinic they might respond
differently. Finally, the vignettes focused on placebo-prescribing
and did not describe the doctors’ motivations. We wanted to
explore patients’ views about doctors deliberately attempting to
elicit a beneficial placebo effect by prescribing a placebo (see
Introduction). However, doctors have a wide range of reasons for
prescribing placebo interventions in clinical practice, some of
which emphasize benefits for the doctor more than the patient (e.g.
to satisfy a patient’s demand for a prescription; to feel able to ‘‘do
something’’; and to manage the clinical uncertainty that can be
common in general practice).[47,48] More qualitative studies are
now needed to explore patients’ views about these other types of
placebo-prescribing that may already be common in practice.[47]
Relation to Other Studies
Previous studies of patients’ views regarding clinical applications
of placebos have used surveys and/or questionnaires.[28–34] Most
recently, Hull and colleagues surveyed adults in the USA to
determine the acceptability of placebo treatments and found that
most, but not all, respondents thought it was acceptable for doctors
to use placebos under some circumstances.[34] However, although
a significant number of patients (21.8% in the Hull et al. study)
thought that placebos were not acceptable under any circum-
stances, the reasoning behind this view was not revealed in the
surveys. Using focus groups in our study allowed us to obtain a
more in-depth understanding of reasoning used to either support
or oppose the use of placebos in the clinic. In particular, our
findings suggest that people who find placebo-prescribing unac-
ceptable do so because of beliefs that (i) placebos are ineffective,
which leads to the view that placebos are a waste of time and
money, and pander to dependency on doctors and medications; (ii)
placebos require deception, which leads to the view that a doctor
who prescribes placebos is not to be trusted, and that patients’
involvement in their own healthcare is compromised; and (iii)
patients that respond to placebos are gullible, foolish, or childish,
leading to the view that they themselves would not want to be
treated in this way. On the other hand, people who find placebo-
prescribing acceptable seem to do so primarily because they
believe placebos can be effective and they prioritize such patient
benefit over other concerns.
Implications
Our findings suggest that placebo-prescribing might be more
acceptable to patients in some circumstances if they understood
better that (i) placebos can trigger improvements in symptoms and
other benefits for patients; (ii) deception may not be necessary for
placebos to be effective (e.g., carefully worded explanations by
doctors could obviate outright lying, more detailed explanations
could lead to belief in placebos, and general consent forms could
be used to give blanket permission to receive placebos); and (iii) the
ability to respond to placebos takes advantage of biological
mechanisms already in place in all humans (and therefore is not
confined to the more ‘gullible’ sector of the population). Some
patients might still deem placebo-prescribing unacceptable and
this view would need to be respected by clinicians and researchers.
Overall, however, it seems critical to find ways to educate patients
about placebos and their effects.
Unanswered Questions and Future Research
We do not know the extent to which our findings have captured
the range of views held among the general public at large.
Therefore, additional research could expand on these findings by
running focus groups in other areas of the UK/elsewhere and with
people from ethnic minorities not reached by this study; our
findings could also be used as the basis to conduct a large-scale
survey of beliefs and knowledge about placebos and placebo
effects. In addition, more research is needed to test the efficacy of
placebo-prescribing in the clinic and to identify the best ways for
doctors to harness placebo effects, taking into account patients’
diverse perspectives.
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Conclusions
Patients are uncertain and express diverse and contradictory
beliefs about the acceptability of placebo-prescribing: some find it
acceptable, for example when they prioritize possible benefits to
patients; others find it unacceptable, for example when they
believe placebo-prescribing must involve deception and thus
violates a patients’ right to self-determination and participation
in healthcare. Public education about placebo effects is needed to
correct misunderstandings. Additional research is warranted to
identify optimal ways of harnessing placebo effects in clinical
practice for patients with diverse views.
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